The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the market. A shift away from Schedule I status, often viewed as outdated and hindering innovation, https://baidubookmark.com/story20587307/pot-rescheduling-a-expansion-catalyst